Drug Resistant Cancer Models

LIDE’s biobank receives fresh patient samples every day from hospitals all over China due to our RWE study on precision medicine. LIDE does in-house analysis of these samples via our MiniPDX assay and bioinformatics capabilities. Below are cell lines and models with validated drug resistance.

Based on 200+ established PDX models that are resistant to specific treatment strategies, LIDE’s conditionally reprogramming (CR) process allows for rapid and efficient expansion of cell cultures from these resistant samples. These CR cells can aid in the discovery of novel strategies to overcome existing resistance.

Cancer Type Drug Resistance Genetic Alteration
NSCLC Erlotnib
Osimertinib
Crizotnib
Brigatnib
anti PD-1 ab
EGFR: exon19del/T790M/L858R/C797S/exon20ins
ALK: EML4-ALK/L11196M
cMET: ampli./exon14ski/CD47-MET
RET: KIF5B-RET
ROS1: CD74-ROS1/G2032R
KRAS: G12C
P13K: E726K
Breast Cancer CDK4/6i TNB/ER+
Multiple Myeloma Bortezomib CD47+/CD38+
Cholangiocarcinoma Paclitaxel KRAS: G12C
FGFR: BICC1-FGFR2
Colorectal Cancer Avastin KRAS: G12C
BFAR: V600E
Hematological Malignancy Rituximab
Imatinib
/
Gastric Cancer Herceptin HER2: ampli
KRAS: G12/G13D
Brain Cancer / EGFR: VIII
cMET: PTPPRZ1-MET
Melanoma anti PD-1 ab BRAF: V600E
Ovarian Cancer Platinum
PARpi
/

Table: LIDE PDX models with drug resistance

Download our model and cell line list here